Hepatocellular Carcinoma Drugs (PD-1/PD-L1 Inhibitors, Tyrosine Kinase Inhibitors) Industry Report 2024: A $1.62 Billion Market Opportunity by 2028
January 24, 2024 13:42 ET
|
Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Hepatocellular Carcinoma Drugs Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.The global hepatocellular...
Global Angina Pectoris Drugs Market Report 2024: Escalating Prevalence of Hypertension and Diabetes Driving Demand for Angina Drugs
January 24, 2024 13:41 ET
|
Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Angina Pectoris Drugs Global Market 2024" report has been added to ResearchAndMarkets.com's offering. The global landscape of angina pectoris drugs...
Melanoma Drugs - $13.98 Billion Industry Opportunity Assessment, 2024-2028: Regional Insights and Competitor Market Shares
January 24, 2024 13:39 ET
|
Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Melanoma Drugs Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.The global melanoma drugs market has grown...
Nephrology Drugs Industry Report 2024-2033: Innovative Therapies, Precision Medicine, Telehealth, and Global Initiatives Driving the Market to Reach $21.53 Billion by 2028
January 24, 2024 13:36 ET
|
Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Nephrology Drugs Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The global nephrology drugs market has grown...
Acute Lymphoblastic Leukemia Treatment Market Poised for Growth, Forecasts 2024-2030: Spotlight on Emerging Therapies and Comprehensive Vendor Analysis
January 24, 2024 08:49 ET
|
Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Global Acute Lymphoblastic Leukemia Treatment Market (ALL) by Types of Cell (B-cell ALL, Philadelphia chromosome: Positive (Ph+) and negative (Ph-),...
Global Pharmaceutical R&D Directory 2024: Development Pipeline of Major Companies, Analyzed by Therapeutic Categories and Stages
January 22, 2024 06:13 ET
|
Research and Markets
Dublin, Jan. 22, 2024 (GLOBE NEWSWIRE) -- The "Global Pharmaceutical R&D Directory 2024" has been added to ResearchAndMarkets.com's offering.The Global Pharmaceutical R&D Directory provides...
Processa Pharmaceuticals to Effect a 1-for-20 Reverse Stock Split
January 18, 2024 07:45 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next...
Global Pharmaceuticals Market Analysis and Forecast to 2027, with Company Profiles of Key Market Players Bayer, Novartis ,Pfizer and Johnson & Johnson
January 04, 2024 09:43 ET
|
Research and Markets
Dublin, Jan. 04, 2024 (GLOBE NEWSWIRE) -- The "Global Pharmaceuticals Market Summary, Competitive Analysis and Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.The...
Processa Pharmaceuticals Provides Interim Analysis from Ongoing Phase 1b Trial of Next Generation Capecitabine Showing Improved Safety Over Capecitabine
December 19, 2023 09:00 ET
|
Processa Pharmaceuticals, Inc.
FDA acknowledges that NGC-Cap is a New Chemical Entity given the changes to metabolism and distribution of its major metabolite 5-FU Interim analysis of the NGC-Cap Phase 1b data shows improved...
Rafarma Pharmaceutical news update
November 30, 2023 09:30 ET
|
Rafarma Pharmaceuticals Inc.
Russia, Moscow, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals (OTC: RAFA). The Company is pleased to announce that it has completed the restructuring, accounting and balance sheet...